NEURO-ONCOLOGY • JUNE 2017 entities. Promising candidates are currently being further characterized, e.g. Panobinostat showed activity in the majority of brain tumor models at low nanomolar concentrations. CONCLUSION: The growing importance of HDAC inhibitors is reflected by an increasing number of HDACi in clinical trials, with four HDACi already approved by the FDA for treating lymphomas and multiple myelomas. Our study supports the finding that HDACi are valid therapeutic agents and that selected inhibitors are promising candidates for future epigenetic therapy of primary brain tumors.
INTRODUCTION: Whole exome sequencing (WES) of newly diagnosed pediatric central nervous system (CNS) tumors is quickly becoming part of routine care. Through the Precision in Pediatric Sequencing (PiPseq) program at Columbia University, we have found potentially actionable mutations in more than 40% of evaluable CNS cases at diagnosis. More recently, we have integrated this approach into the management of patients undergoing surgery for CNS tumor recurrence. METHOD: After obtaining informed consent, tumor-normal WES with transcriptome analysis was performed in a CLIA-certified laboratory on fresh frozen or paraffin embedded CNS tumor samples and peripheral blood. RESULTS: 7 cases (5 male, 2 female; median age 5 years) with adequate diagnostic and recurrent tumor tissue were tested. No case had a somatic mutation of established clinical utility (tier 1). Among 3 embryonal tumors, a splice site variant in TSC1 (tier 2 mutation of potential utility) was detected in a medulloblastoma, but only at recurrence and not at initial diagnosis. FOXR2 overexpression was detected at diagnosis and confirmed at early progression of a temporal lobe tumor, prompting revision of the initial diagnosis of high grade glioma to CNS neuroblastoma subtype of PNET, and treated accordingly. In a third patient initially diagnosed with medulloblastoma, overexpression of PDGFRA, MDM4, CDKN2A, EGFR, OLIG2, and GFAP supported a change in diagnosis to glioblastoma. Two gliomas had tier 2 mutations detected at initial diagnosis and progression: SETD2 p.R2040* (optic nerve lesion, called pseudotumor initially but glioma at progression), and H3F3A p.K28M (thalamic low grade glioma). In one patient with ependymoma, copy number gain of 1q25 (associated with poor prognosis) was seen only in the recurrence specimen. CONCLUSION: Our preliminary experience suggests that in pediatric CNS tumor patients referred for reoperation at recurrence, repeat WES may reveal a previously unrecognized treatment option, at least in embryonal tumors. INTRODUCTION: MLN0128, a second-generation ATP-competitive pan-mTOR kinase inhibitor, acts on both mTORC1 and mTORC2. We investigated the effects of MLN0128 monotherapy and in combination with MEK and BRAFV600E inhibition in models of pediatric low-grade glioma (PLGG). METHODS: We used human glioma cell lines expressing BRAF V600E (AM38), wild-type BRAF (LN229, TN98, SF188) and isogenic systems of KIAA1549:BRAF-expressing NIH3T3 cells. Signaling inhibitors included MLN0128, everolimus, BRAF V600E specific inhibitor PLX4720, and MEK specific inhibitors AZD6244 and GSK1120212. Cell proliferation was determined using an ATP-based assay. Biochemical effects were assessed using western blot analysis. The DBTRG (BRAF V600E ) xenograft mouse model was used to assess in vivo efficacy. RESULTS: MLN0128 monotherapy demonstrates more potent anti-proliferative effects compared to everolimus in all tested PLGG lines independent of BRAF status. As expected, treatment with MLN0128 leads to down-regulation of p-AKT, p-S6 and p-4EBP1, whereas treatment with everolimus only reduces expression of p-S6. MEK inhibition with AZD6244 effectively decreases p-ERK expression in all lines; however, the addition of MLN0128 to AZD6244 causes a rebound in p-ERK expression in BRAF WT gliomas but not in gliomas expression BRAF V600E or KIAA1549:BRAF alterations. In cells carrying either the BRAF V600E or KIAA1549:BRAF alteration, combined treatment with MLN0128 and GSK1120212 or AZD6244 leads to synergistic anti-proliferative effects but such synergy is not evident in BRAF WT gliomas. In vivo studies show superior efficacy of combinations of PLX4720 and MLN0128 compared to monotherapies (p<0.02) or combination of PLX4720 + everolimus (p=0.03). CONCLUSION: MLN0128 displays synergistic anti-neoplastic effects with MEK inhibition in gliomas bearing BRAF V600E or KIAA1549:BRAF. In BRAF wild-type cells such synergy is not present, potentially due to rebound in p-ERK when MLN0128 is combined with AZD6244. Combination therapy with MLN0128 + PLX4720 prolongs survival in a BRAF V600E mutant glioma model and is superior to monotherapy or everolimus + PLX4720 combination.
TRTH-31. EFFECTS OF TORC1/2 INHIBITOR MLN0128 ALONE AND IN COMBINATION WITH MEK INHIBITION IN BRAF MUTATED GLIOMA CELLS

TRTH-32. COMBINATION IMMUNOTHERAPY TO ACTIVATE THE INNATE IMMUNE MICROENVIRONMENT AGAINST PEDIATRIC BRAIN TUMORS
Sharareh Gholamin, Rogelio Esparza, Samuel Cheshier, and Siddhartha Mitra; Stanford University School of Medicine, Stanford, CA, USA.
Currently combinations of surgery, chemotherapy, and irradiation are utilized to treat pediatric malignant brain tumors; resulting in significant and permanent morbidity. Recently we published the effect of a humanized anti-CD47 antibody, Hu5F9-G4, on five aggressive and etiologically distinct pediatric brain tumors: Group 3 medulloblastoma (primary and metastatic), atypical teratoid rhabdoid tumor, primitive neuroectodermal tumor, pediatric glioblastoma, and diffuse intrinsic pontine glioma. Hu5F9-G4 demonstrated therapeutic efficacy in vitro and in vivo in patient-derived orthotopic xenograft models. Disabling the inhibitory signals transduced by SIRPa by blocking anti-CD47 antibodies we reduce the threshold for macrophage activation and promote phagocytic response driven by tumor-specific antibodies. Consequently, a number of approaches to augment macrophage responses to therapeutic antibodies are under investigation, including the exploration of new targets and development of antibodies with enhanced functions. We tested a unique paradigm to fully utilize the innate immune system by utilizing a three-pronged approach. a) Increase the infiltration of macrophages into the tumor. b) Block the anti-phagocytic signals and c) Stimulate pro-phagocytic signals. RESULTS: To determine the in vivo efficacy of combinatorial anti-CD47 and anti-CD40 therapies, Group 3 medulloblastoma xenografts were treated by, i.p. injections with either PBS (control), anti-CD47, anti-CD40 or anti-CD47+ anti-CD40 mAbs. Mice receiving anti-CD47 anti-CD40 duotherapy demonstrated increased survival as compared to both monotherapies and control cohorts. Immunohistochemical staining with the macrophage marker F4/80 demonstrated varying patterns of macrophage infiltration and combined anti-CD47 anti-CD40 therapy demonstrated increase macrophage recruitment and intra-tumor macrophage distribution in comparison to both monotherapeutic approaches. Antibody-dependent phagocytosis of solid tumors has also been demonstrated in vitro using anti-Her2 antibodies against breast cancer. To test if Herceptin (Trastuzumab) had similar opsonizing effect on MB cells, we carried out in-vitro in-vivo assays in combination with anti-CD47 and observe a synergistic effect of combination treatment. PURPOSE: BRAF V600E mutations are present in several pediatric CNS tumors, particularly pilocytic astrocytomas, gangliogliomas and pleomorphic xanthochromic astrocytomas. Several BRAF inhibitors are under clinical investigation, alone and in combination with MEK inhibitors. To guide the clinical development of BRAF and MEK inhibitors, we evaluated CNS penetration of dabrafenib, selumetinib, vemurafenib, and trametinib (using CSF as a surrogate) in a nonhuman primate model predictive of pharmacokinetics (PK) in pediatric populations. METHODS: This study was approved by the NCI Animal Care and Use Committee. Agents were administered orally to rhesus macaques (n=4), with human equivalent dosing as follows: dabrafenib (161 mg/m 2 ) and selumetinib (50 mg/m 2 ). Planned studies include vemurafenib (516 mg/m 2 ) and trametinib (1.1 mg/m 2 ). Serial, paired plasma and CSF samples were collected from 0-24 hr for dabrafenib and 0-48 hr for selumetinib. Dabrafenib was quantified using a validated ultra HPLC-MS/ MS method (lower limit of quantitation (LLOQ) in plasma and CSF = 1 and 0.1 ng/mL, respectively). Selumetinib was quantified by Covance Bioanalytical Services (LLOQ = 0.5 ng/mL in plasma and CSF). PK parameters were calculated using noncompartmental methods. RESULTS: In plasma, mean half-life and dose-normalized AUC inf for dabrafenib were 3.2 (±1.2) hr and 73.9 (±34.0) hr*ng/mL/mg, respectively, and for selumetinib, 10.8 (± 2.5) hr and 122 (± 17.8) hr*ng/mL/mg, respectively. In CSF, 5.0 (±1.7) hr and 0.43 (±0.21) hr*ng/mL/mg, respectively. CSF levels of selumetinib were detectable in one animal, with an AUC inf of 0.39 hr*ng/mL/mg. CSF penetration of dabrafenib and selumetinib were poor (0.57 (±0.18) % and 0.4%, respectively). CONCLUSIONS: Quantifiable concentrations of dabrafenib were found in plasma and CSF for 24 hr after administration, but, as with selumetinib, CSF penetration was low. Due to inter-animal variability, an additional animal will be studied. Alternate delivery methods (intranasal and intrathecal) may be useful to evaluate in efforts to increase CNS exposure.
TRTH-33. COMPARATIVE PLASMA AND CEREBROSPINAL FLUID PHARMACOKINETICS OF BRAF AND MEK INHIBITORS IN A NONHUMAN PRIMATE MODEL
TRTH-34. NOVEL ORAL PRODRUGS OF 6-DIAZO-5-OXO NORLEUCINE IMPROVE BRAIN PENETRATION AND DEMONSTRATE EFFICACY AGAINST MYC-DRIVEN ORTHOTOPIC MEDULLOBLASTOMA XENOGRAFTS
Allison Hanaford, Charles Eberhart, and Eric Raabe; Johns Hopkins Medicine, Baltimore, MD, USA.
Increased MYC levels can alter cellular metabolism, creating a reliance on glutamine. Glutamine PET and MRI spectroscopy demonstrate that aggressive brain malignancies have increased uptake of glutamine and increased glutamate relative to normal brain, suggesting that agents targeting glutamine metabolism may be active in brain tumors. The most aggressive subgroup of medulloblastoma tumors are driven by high expression of MYC, so we hypothesized that these tumors would have altered glutamine metabolism and be sensitive to 6-diazo-5-oxo norluecine (DON), a glutamine analog. Western blotting revealed that expressing MYC in human cerebellar-derived neural stem and progenitor cells (CB NSC) induced the expression of glutaminase (GLS), the enzyme that converts glutamine to glutamate-a critical step in glutamine metabolism. Human neural stem cells transformed with SV40 do not express MYC and thus do not express GLS. MYC-expressing patient-derived medulloblastoma cell lines (D425MED and D283MED) also express GLS. We treated our MYC-transformed CB NSC and medulloblastoma cell lines with DON and observed an increase in apoptosis of up to 450% as determined by cleaved caspase-3 immunofluorescence (p=0.001). DON treatment did not significantly increase apoptosis in SV40-immortablized CB NSC (p=0.65) and had no effect on normal, untransformed human NSC. DON is not orally bioavailable, so we decided to develop DON prodrugs designed for improved oral bioavailability and brain penetration. In non-human primates, our DON prodrug exhibited superior 10-fold enhanced CSF/plasma ratio versus DON. In orthotopic xenograft models, our novel DON prodrugs increased the median survival of mice bearing D425-MED MYC-driven medulloblastoma tumors by 60 percent (22 days for vehicle treated mice compared to 35 days for prodrug treated mice, p<0.01 by log-rank test). DON prodrugs can be engineered to improve oral bioavailability and brain penetration, and these drugs have efficacy in orthotopic xenograft models of aggressive MYC-driven medulloblastoma tumors.
